Lupus & antiphospholipid syndrome
Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study
Authors' conclusion
LAMDA is a novel ultrasound-derived clinical disease activity measure that should improve the assessment of lupus arthritis in clinical trials and real-world practice.
Study context
- Population
- Participants with systemic lupus erythematosus (SLE) receiving intramuscular GC therapy for lupus arthritis, seven hospitals in England; external validation cohort from Leeds
- Participants
- 133 vs 44
- Exposure
- USEFUL vs External validation
- USEFULn = 133
- External validationn = 44
- Outcome
- Derivation of the LAMDA score against total combined grey scale and power Doppler hand and wrist US scores
Methodological detailsinstrument derivation and validation, prospective, longitudinal, multicentre, external validation cohort, penalised multiple quantile (median) regression, ROC curve analysis, People with lived experience of SLE were involved in the design and delivery
- Instrument derivation and validation
- Prospective
- Longitudinal
- Multicentre
- External validation cohort
- Penalised multiple quantile (median) regression
- ROC curve analysis
- People with lived experience of SLE were involved in the design and delivery
Main finding
As reported in the abstract
Intraclass correlation supporting substitution of swollen joint count in 28 joints for 66 joints
>0.99
Responsiveness: early treatment effect after GC therapy, effect size (p<0.0001)
0.40
Observational data: associations, not effects.
Further findings
External validation cohort
- Findings supportive of the initial findings
- LAMDA correlated with multiple participant reported outcome measures
- Proposed thresholds outperformed swollen joint counts alone in discriminating treatment intention and participant acceptable symptom state
Original publication
Derivation, validation, and proposed thresholds of the Lupus Arthritis and Musculoskeletal Disease Activity (LAMDA) instrument: a cohort study. Lancet Rheumatol. Published 2 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →